194 related articles for article (PubMed ID: 26831669)
1. Trichostatin A potentiates TRAIL-induced antitumor effects via inhibition of ERK/FOXM1 pathway in gastric cancer.
Li L; Fan B; Zhang LH; Xing XF; Cheng XJ; Wang XH; Guo T; Du H; Wen XZ; Ji JF
Tumour Biol; 2016 Aug; 37(8):10269-78. PubMed ID: 26831669
[TBL] [Abstract][Full Text] [Related]
2. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
Biochem Pharmacol; 2009 Apr; 77(8):1328-36. PubMed ID: 19426671
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel enhances tumoricidal potential of TRAIL via inhibition of MAPK in resistant gastric cancer cells.
Li L; Wen XZ; Bu ZD; Cheng XJ; Xing XF; Wang XH; Zhang LH; Guo T; Du H; Hu Y; Fan B; Ji JF
Oncol Rep; 2016 May; 35(5):3009-17. PubMed ID: 26986870
[TBL] [Abstract][Full Text] [Related]
4. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells.
Sung ES; Kim A; Park JS; Chung J; Kwon MH; Kim YS
Apoptosis; 2010 Oct; 15(10):1256-69. PubMed ID: 20582477
[TBL] [Abstract][Full Text] [Related]
6. Trichostatin A sensitizes TRAIL-resistant myeloma cells by downregulation of the antiapoptotic Bcl-2 proteins.
Fandy TE; Srivastava RK
Cancer Chemother Pharmacol; 2006 Oct; 58(4):471-7. PubMed ID: 16435155
[TBL] [Abstract][Full Text] [Related]
7. ERK inhibition enhances TSA-induced gastric cancer cell apoptosis via NF-κB-dependent and Notch-independent mechanism.
Yao J; Qian CJ; Ye B; Zhang X; Liang Y
Life Sci; 2012 Sep; 91(5-6):186-93. PubMed ID: 22781708
[TBL] [Abstract][Full Text] [Related]
8. Restoration of XAF1 expression induces apoptosis and inhibits tumor growth in gastric cancer.
Tu SP; Liston P; Cui JT; Lin MC; Jiang XH; Yang Y; Gu Q; Jiang SH; Lum CT; Kung HF; Korneluk RG; Wong BC
Int J Cancer; 2009 Aug; 125(3):688-97. PubMed ID: 19358264
[TBL] [Abstract][Full Text] [Related]
9. Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade.
Reddy RM; Yeow WS; Chua A; Nguyen DM; Baras A; Ziauddin MF; Shamimi-Noori SM; Maxhimer JB; Schrump DS; Nguyen DM
Apoptosis; 2007 Jan; 12(1):55-71. PubMed ID: 17136498
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells via suppression of Bcl-xL.
Cha HY; Lee BS; Chang JW; Park JK; Han JH; Kim YS; Shin YS; Byeon HK; Kim CH
Cancer Lett; 2016 Mar; 372(1):65-74. PubMed ID: 26721202
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.
Okada K; Fujiwara Y; Takahashi T; Nakamura Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
Ann Surg Oncol; 2013 Mar; 20(3):1035-43. PubMed ID: 23054116
[TBL] [Abstract][Full Text] [Related]
12. Metformin synergistically enhances antitumor activity of histone deacetylase inhibitor trichostatin a against osteosarcoma cell line.
Duo J; Ma Y; Wang G; Han X; Zhang C
DNA Cell Biol; 2013 Apr; 32(4):156-64. PubMed ID: 23451817
[TBL] [Abstract][Full Text] [Related]
13. Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma.
Lin WC; Hsu FS; Kuo KL; Liu SH; Shun CT; Shi CS; Chang HC; Tsai YC; Lin MC; Wu JT; Kuo Y; Chow PM; Liao SM; Yang SP; Hong JY; Huang KH
J Mol Med (Berl); 2018 Dec; 96(12):1307-1318. PubMed ID: 30288546
[TBL] [Abstract][Full Text] [Related]
14. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
[TBL] [Abstract][Full Text] [Related]
15. Antitumor Effect of Periplocin in TRAIL-Resistant gastric cancer cells via upregulation of death receptor through activating ERK1/2-EGR1 pathway.
Zhao LM; Li L; Huang Y; Han LJ; Li D; Huo BJ; Dai SL; Xu LY; Zhan Q; Shan BE
Mol Carcinog; 2019 Jun; 58(6):1033-1045. PubMed ID: 30737960
[TBL] [Abstract][Full Text] [Related]
16. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression.
Shrader M; Pino MS; Lashinger L; Bar-Eli M; Adam L; Dinney CP; McConkey DJ
Cancer Res; 2007 Feb; 67(4):1430-5. PubMed ID: 17308080
[TBL] [Abstract][Full Text] [Related]
18. Irigenin sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells.
Xu Y; Gao CC; Pan ZG; Zhou CW
Biochem Biophys Res Commun; 2018 Feb; 496(3):998-1005. PubMed ID: 29305260
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N
BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472
[TBL] [Abstract][Full Text] [Related]
20. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
